Across TCGA pan-cancer cohorts, CXCL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CXCL1 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher CXCL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL1 expression acts as an unfavorable survival marker.
COAD and LIHC are the cancer types where CXCL1 Mutation most reproducibly stratifies survival.